melior discovery

About Us
Our Pipeline
Our Platform
Partnering with Us
News
Contact Us

Click here for the MLR-1023 non-confidential brochure          

melior melior discovery

Our Pipeline MLR-1017 (Parkinson's Disease)

Melior Pharmaceuticals pipeline

Click chart for a larger view.

Melior Discovery is currently developing MLR-1017 as an adjunctive therapy with L-DOPA for the treatment of Parkinson's disease. The activity of MLR-1017 was identified using Melior's phenotypic screening platform theraTRACE®. In preclinical animal models, MLR-1017 has the unique properties of enhancing the therapeutic benefit of L-DOPA while simultaneously blocking L-DOPA-induced movement disorders. In animal models of Parkinson's disease MLR-1017 outperforms all clinically used drugs as well as development stage L-DOPA adjunctive candidates for this therapeutic indication.

Parkinson's disease is a nigrostriatal dopaminergic neurodegenerative disorder that affects 1% of people over the age of 60. This disease is effectively, but temporarily, treated with the dopamine precursor L-DOPA. L-DOPA treatment results in elevated levels of dopamine in the brain that, in turn, transiently reverses the motor dysfunction of Parkinson's disease. However, long-term use of L-DOPA induces complications such as dyskinesia (abnormal movements) and tolerance, referred to as "wearing-off". Nearly all L-DOPA treated PD patients develop some form of debilitating dyskinesia. Dyskinesias evoke a major negative impact on quality of life that can be more disabling than the disease itself. Importantly, the existence or threat of L-DOPA-induced dyskinesias limits L-DOPA dosage that can be safely administered to patients.

MLR-1017 is a neuroactive drug that has been used in Eastern Europe for the treatment of several neurological disorders. In humans, MLR-1017 is safe, well-tolerated and does not cause abuse liability. However, MLR-1017 has never been evaluated in Parkinson's disease patients as a monotherapy or as an adjunct to L-DOPA treatment. Melior has proprietary positions on method-of-use of MLR-1017 and composition-of-matter in combination with L-DOPA.

If you are interested in learning more about MLR-1017, please contact bizdev@meliordiscovery.com to start the conversation.

Back to top of page

 
home